Valuation: CSL Limited

Market Cap 40.42B 35.45B 32.84B 30.21B 57.14B 3,869B 58.26B 391B 153B 1,900B 152B 148B 6,561B P/E 2026 *
-45.4x
P/E 2027 * 28.1x
Enterprise Value 49.27B 43.21B 40.02B 36.83B 69.66B 4,716B 71.01B 477B 187B 2,316B 185B 181B 7,997B EV / Sales 2026 *
3.2x
EV / Sales 2027 * 3.1x
Free-Float
99.3%
Yield 2026 *
3.38%
Yield 2027 * 3.47%
1 day-1.17%
1 week-3.98%
Current month+6.96%
1 month+11.92%
3 months-13.78%
6 months-31.02%
Current year-28.99%
1 week 16.9
Extreme 16.9
17.9
1 month 14.6
Extreme 14.6
17.9
Current year 12.7
Extreme 12.7
43.4
1 year 12.7
Extreme 12.7
43.4
3 years 12.7
Extreme 12.7
47.5
5 years 12.7
Extreme 12.7
51
10 years 12.7
Extreme 12.7
52.5
Manager TitleAgeSince
Chief Executive Officer 63 11/02/2026
Director of Finance/CFO 52 07/10/2025
Chief Operating Officer - 01/05/2025
Director TitleAgeSince
Director/Board Member 72 17/10/2018
Director/Board Member 70 02/02/2011
Director/Board Member 71 09/12/2019
Change 5-day change 1-year change 3-year change Capi.($)
-1.17%-3.98% - - 40.94B
-0.51%+1.55%+15.65%-8.48% 67.61B
-0.63%-7.39%+36.54%+199.82% 51.6B
+0.36%+40.00%+40.00%+40.00% 43B
+2.95%-2.56%+52.59%-26.93% 29.4B
-0.71%-17.05%+106.42%-46.41% 27.09B
-1.74%-1.15%+63.32%+84.52% 23.32B
-0.67%+1.48%+10.61%+188.35% 19.92B
-2.12%-3.92%+56.13%+130.60% 16.91B
-4.62%+5.41%+71.85%+373.45% 16.84B
Average -0.89%-2.13%+50.35%+103.88% 32.85B
Weighted average by Cap. -0.59%-2.79%+43.76%+79.91%

Financials

2026 *2027 *
Net sales 15.39B 13.5B 12.5B 11.5B 21.76B 1,473B 22.18B 149B 58.45B 723B 57.8B 56.53B 2,498B 15.64B 13.71B 12.7B 11.69B 22.1B 1,496B 22.53B 151B 59.37B 735B 58.71B 57.43B 2,538B
Net income -894M -784M -726M -668M -1.26B -85.52B -1.29B -8.65B -3.39B -42B -3.36B -3.28B -145B 1.18B 1.04B 961M 884M 1.67B 113B 1.71B 11.46B 4.49B 55.61B 4.44B 4.35B 192B
Net Debt 8.85B 7.76B 7.19B 6.61B 12.51B 847B 12.75B 85.68B 33.6B 416B 33.23B 32.5B 1,436B 8.07B 7.08B 6.56B 6.03B 11.41B 772B 11.63B 78.14B 30.65B 379B 30.3B 29.64B 1,310B
Logo CSL Limited
CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with approximately 325 plasma collection centers in the United States, Europe and China. The Company operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China (including Hong Kong). Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam, and others.
Employees
29,904
Date Price Change
13/07/26 EUR 16.90 -1.17%
10/07/26 EUR 17.10 -2.84%
09/07/26 EUR 17.60 -1.12%
08/07/26 EUR 17.80 -0.56%
07/07/26 EUR 17.90 +1.70%
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
84.40USD
Average target price
96.64USD
Spread / Average Target
+14.50%

Quarterly revenue - Rate of surprise